Search | OpenScholar

Search results

193 results found

Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.

Publication: Journal Article

Hermanowicz, N, SA Jones, and RA Hauser. 2019. “Impact of Non-Motor Symptoms in Parkinson’s Disease: A PMDAlliance Survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.”. Neuropsychiatry Dis Treat.

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018;389:10-16.

Publication: Journal Article

“Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The Nosology of Tardive Syndromes. J Neurol Sci 2018;389:10-16.”. 2018. J Neurol Sci.

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.

Publication: Journal Article

Bajaj, N, RA Hauser, and ID Grachev. 2013. “Clinical Utility of Dopamine Transporter Single Photon Emission CT (DaT-SPECT) With (123I) Ioflupane in Diagnosis of Parkinsonian Syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.”. J Neurol Neurosurg Psychiatry.

[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected Parkinsonian syndromes. J Neuroimaging 2012;22:225-30.

Publication: Journal Article

Hauser, RA, and DG Grosset. 2012. “[123I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients With Suspected Parkinsonian Syndromes. J Neuroimaging 2012;22:225-30.”. J Neuroimaging.

The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. Int J Neurosci 2012;122:333-7.

Publication: Journal Article

Hauser, RA, KE Lyons, and R Pahwa. 2012. “The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson’s Disease. Int J Neurosci 2012;122:333-7.”. Int J Neurosci.

Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci 2017;373:116-123.

Publication: Journal Article

Tetrud, J, P Nausieda, D Kreitzman, GS Liang, A Nieves, AP Duker, RA Hauser, et al. 2017. “Conversion to Carbidopa and Levodopa Extended-Release (IPX066) Followed by Its Extended Use in Patients Previously Taking Controlled-Release Carbidopa-Levodopa for Advanced Parkinson’s Disease. J Neurol Sci 2017;373:116-123.”. J Neurol Sci.

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.

Publication: Journal Article

Hauser, RA, SA Factor, SR Marder, MA Knesevich, PM Ramirez, , J Burke, GS Liang, and CF O’Brien. 2017. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.”. Am J Psychiatry.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Mov Disord 2017;32:783-789.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Leinonen, N Giladi, RA Hauser, OS Klepiskaya, DL Kreitzman, et al. 2017. “A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease. Mov Disord 2017;32:783-789.”. Mov Disord.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology 2017;88:2003-2010.

Publication: Journal Article

Fernandez, HH, SA Factor, RA Hauser, J Jimenez-Shahed, and . 2017. “Randomized Controlled Trial of Deutetrabenazine for Tardive Dyskinesia: The ARM-TD Study. Neurology 2017;88:2003-2010.”. Neurology.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord 2016;31:1356-65.

Publication: Journal Article

LeWitt, PA, RA Hauser, DG Grosset, F Stocchi, MH Saint-Hilaire, A Ellenbogen, M Leinonen, et al. 2016. “A Randomized Trial of Inhaled Levodopa (CVT-301) for Motor Fluctuations in Parkinson’s Disease. Mov Disord 2016;31:1356-65.”. Mov Disord.